The identification of the KDM6A/YY1/TRKA axis as a novel imatinib-resistance mechanism represents an unexplored avenue to overcome TKI resistance in CML. This evidence concerns the gene NTRK1 and chronic myelogenous leukemia, BCR-ABL1 positive.